

Allergic Conjunctivitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/A73DC63B82EFEN.html>

Date: August 2022

Pages: 77

Price: US\$ 2,000.00 (Single User License)

ID: A73DC63B82EFEN

Abstracts

Allergic Conjunctivitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Allergic Conjunctivitis - Drugs In Development, 2022, provides an overview of the Allergic Conjunctivitis (Ophthalmology) pipeline landscape.

Allergic conjunctivitis occurs when the clear layer of tissue lining the eyelids and covering the white of the eye (conjunctiva) become swollen or inflamed due to a reaction to pollen, dander, mold, or other allergy-causing substances. Symptoms include intense itching, puffy eyelids, widened (dilated) vessels in the clear tissue covering the white of the eye and stringy eye discharge. Treatment includes antihistamine or anti-inflammatory medication.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Allergic Conjunctivitis - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Allergic Conjunctivitis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Allergic Conjunctivitis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Allergic Conjunctivitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 5, 8, 2, 10 and 1 respectively.

Allergic Conjunctivitis (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Allergic Conjunctivitis (Ophthalmology).

The pipeline guide reviews pipeline therapeutics for Allergic Conjunctivitis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Allergic Conjunctivitis (Ophthalmology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Allergic Conjunctivitis (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Allergic Conjunctivitis (Ophthalmology)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Allergic Conjunctivitis (Ophthalmology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Allergic Conjunctivitis (Ophthalmology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and

understand from the know-how what drove them from pipeline.

Contents

Introduction

Global Markets Direct Report Coverage

Allergic Conjunctivitis - Overview

Allergic Conjunctivitis - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Allergic Conjunctivitis - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Allergic Conjunctivitis - Companies Involved in Therapeutics Development

Accolade Pharmaceuticals LLC

Aldeyra Therapeutics Inc

Alexion Pharmaceuticals Inc

ALK-Abello AS

Allakos Inc

Boehringer Ingelheim International GmbH

Clevexel Pharma SA

Faes Farma SA

IACTA Pharmaceuticals Inc

Intas Pharmaceuticals Ltd

JW Pharmaceutical Corp

Kissei Pharmaceutical Co Ltd

Nanomerics Ltd

NicOx SA

Ocular Therapeutix Inc

OKYO Pharma Ltd

Oyster Point Pharma Inc

Quark Pharmaceuticals Inc

RAPT Therapeutics Inc

Satellos Bioscience Inc

SIFI SpA

Siolta Therapeutics Inc

Sylentis SAU

Vanda Pharmaceuticals Inc

Wuhan Yicheng Biotechnology Co Ltd

Allergic Conjunctivitis - Drug Profiles

bertilimumab - Drug Profile

Product Description

Mechanism Of Action

History of Events

bilastine - Drug Profile

Product Description

Mechanism Of Action

History of Events

birch pollen allergen extract - Drug Profile

Product Description

Mechanism Of Action

cetirizine hydrochloride - Drug Profile

Product Description

Mechanism Of Action

History of Events

CVXL-0074 - Drug Profile

Product Description

Mechanism Of Action

History of Events

epinastine hydrochloride - Drug Profile

Product Description

Mechanism Of Action

History of Events

IC-265 - Drug Profile

Product Description

Mechanism Of Action

History of Events

IC-270 - Drug Profile

Product Description

Mechanism Of Action

History of Events

KCE-210 - Drug Profile

Product Description

Mechanism Of Action

ketotifen SR - Drug Profile

Product Description

Mechanism Of Action

History of Events

lipidated tacrolimus - Drug Profile

Product Description

Mechanism Of Action

lirentelimab - Drug Profile

Product Description

Mechanism Of Action

History of Events

NM-134 - Drug Profile

Product Description

Mechanism Of Action

OC-103 - Drug Profile

Product Description

Mechanism Of Action

OKYO-0101 - Drug Profile

Product Description

Mechanism Of Action

History of Events

PH-006 - Drug Profile

Product Description

Mechanism Of Action

PRT-2761 - Drug Profile

Product Description

Mechanism Of Action

History of Events

QPI-1020R - Drug Profile

Product Description

Mechanism Of Action

reproxalap - Drug Profile

Product Description

Mechanism Of Action

History of Events

RPT-193 - Drug Profile

Product Description

Mechanism Of Action

Small Molecule to Antagonize Histamine 4 Receptor for Age Related Macular Degeneration and Allergic Conjunctivitis - Drug Profile

Product Description

Mechanism Of Action

STMC-103H - Drug Profile

Product Description

Mechanism Of Action

History of Events

SYL-116011 - Drug Profile

Product Description

Mechanism Of Action

History of Events

VSJ-110 - Drug Profile

Product Description

Mechanism Of Action

History of Events

Yipiwutai - Drug Profile

Product Description

Mechanism Of Action

Zafi-2 - Drug Profile

Product Description

Mechanism Of Action

Allergic Conjunctivitis - Dormant Projects

Allergic Conjunctivitis - Discontinued Products

Allergic Conjunctivitis - Product Development Milestones

Featured News & Press Releases

Mar 01, 2022: Nicox's partner Ocumension obtains positive phase 3 clinical trial results for ZERVIAE in China

Feb 01, 2022: Aldeyra Therapeutics announces publication of phase 2 clinical trial of reproxalap in allergen chamber model

Jan 05, 2022: Nicox European patent seals ZERVIAE major market coverage to 2030

Jul 05, 2021: Nicox to receive \$2 million from Ocumension Therapeutics as advance milestone payment under ZERVIAE agreement

Apr 27, 2021: Aldeyra Therapeutics achieves statistical significance for primary endpoint and all secondary endpoints in phase 3 INVIGORATE clinical trial of Reproxalap in allergic conjunctivitis

Apr 26, 2021: Aldeyra Therapeutics schedules conference call and webcast to announce top-line results from the phase 3 INVIGORATE clinical trial

Dec 30, 2020: Nicox's partner Ocumension Therapeutics initiates ZERVIAE phase 3 clinical trial in China

Oct 26, 2020: Vanda Pharmaceuticals receives FDA approval to proceed with Investigational New Drug VSJ-110 for allergic conjunctivitis

Oct 22, 2020: Aldeyra to present new Reproxalap data from phase 2 clinical trial in

allergic conjunctivitis at American Academy of Ophthalmology 2020 Annual Meeting

Sep 22, 2020: Nicox's ZERVIAE receives IND approval in China

May 21, 2020: Allakos announces multiple presentations related to eosinophil and mast cell-driven diseases at the digital EAACI Annual Congress 2020

May 11, 2020: Allakos announces a presentation of antolimab in patients with severe allergic conjunctivitis at the 2020 ASCRS Virtual Annual Meeting

Mar 30, 2020: Eyevance Pharmaceuticals launches ZERVIAE in the United States

Feb 24, 2020: Aldeyra Therapeutics to provide update on late-stage clinical development pipeline at 2020 Research & Development Day

Jan 22, 2020: Aldeyra Therapeutics begins enrolment in allergic conjunctivitis study

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Allergic Conjunctivitis, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Allergic Conjunctivitis - Pipeline by Accolade Pharmaceuticals LLC, 2022
Allergic Conjunctivitis - Pipeline by Aldeyra Therapeutics Inc, 2022
Allergic Conjunctivitis - Pipeline by Alexion Pharmaceuticals Inc, 2022
Allergic Conjunctivitis - Pipeline by ALK-Abello AS, 2022
Allergic Conjunctivitis - Pipeline by Allakos Inc, 2022
Allergic Conjunctivitis - Pipeline by Boehringer Ingelheim International GmbH, 2022
Allergic Conjunctivitis - Pipeline by Clevexel Pharma SA, 2022
Allergic Conjunctivitis - Pipeline by Faes Farma SA, 2022
Allergic Conjunctivitis - Pipeline by IACTA Pharmaceuticals Inc, 2022
Allergic Conjunctivitis - Pipeline by Intas Pharmaceuticals Ltd, 2022
Allergic Conjunctivitis - Pipeline by JW Pharmaceutical Corp, 2022
Allergic Conjunctivitis - Pipeline by Kissei Pharmaceutical Co Ltd, 2022
Allergic Conjunctivitis - Pipeline by Nanomerics Ltd, 2022
Allergic Conjunctivitis - Pipeline by NicOx SA, 2022
Allergic Conjunctivitis - Pipeline by Ocular Therapeutix Inc, 2022
Allergic Conjunctivitis - Pipeline by OKYO Pharma Ltd, 2022
Allergic Conjunctivitis - Pipeline by Oyster Point Pharma Inc, 2022
Allergic Conjunctivitis - Pipeline by Quark Pharmaceuticals Inc, 2022
Allergic Conjunctivitis - Pipeline by RAPT Therapeutics Inc, 2022
Allergic Conjunctivitis - Pipeline by Satellos Bioscience Inc, 2022
Allergic Conjunctivitis - Pipeline by SIFI SpA, 2022
Allergic Conjunctivitis - Pipeline by Siolta Therapeutics Inc, 2022
Allergic Conjunctivitis - Pipeline by Sylentis SAU, 2022
Allergic Conjunctivitis - Pipeline by Vanda Pharmaceuticals Inc, 2022
Allergic Conjunctivitis - Pipeline by Wuhan Yicheng Biotechnology Co Ltd, 2022
Allergic Conjunctivitis - Dormant Projects, 2022
Allergic Conjunctivitis - Dormant Projects, 2022 (Contd..1)
Allergic Conjunctivitis - Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development for Allergic Conjunctivitis, 2022
Number of Products under Development by Companies, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022

I would like to order

Product name: Allergic Conjunctivitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/A73DC63B82EFEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A73DC63B82EFEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

